knowledge -WSS

knowledge

author：leisure time 2025-09-28 15:56:51 - browse：2

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： PBM reform efforts get punted in Congress

Wikipedia

explore

WSS

Biden calls for immediate release of Niger's president amid apparent coup

Alabama IVF ruling threatens families facing fatal genetic disease

Dario to buy mental health app maker Twill in cash and stock deal

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Alabama frozen embryo ruling has major implications for IVF clinics

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

hotspot

knowledge

leisure time

Walensky prepares to leave CDC — and Congress — behind

Dario to buy mental health app maker Twill in cash and stock deal

In Memoriam: Notable people who died in 2023

With competition flaring, obesity drug hits goal in liver disease study

Trump demands the U.S. pay no more for drugs than other countries … again

'Ancient DNA,' 23andMe reveal African American ancestries

Medicare details structure of new drug price negotiation program

PBM reform efforts get punted in Congress

Activists slam private health insurers over coverage restrictions

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

hotspot

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Stem cell clinics for heart failure: buyer be wary

'Ancient DNA,' 23andMe reveal African American ancestries

ProMED, early warning system on disease outbreaks, in peril

Attacks on the drug industry will lead to fewer breakthroughs

hotspot

Wikipedia

explore

focus